Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab vs placebo and ustekinumab in adolescents with moderate-to-severe plaque psoriasis
NL-OMON52843Phase 3Withdrawn
- Sponsor
- LEO Pharma
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brodalumab in plaque psoriasis, sponsored by LEO Pharma. Primary endpoint: PASI 75 response at Week 12. Planned start Sep 2020; status: withdrawn.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON52843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52843.